Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From what I have read with a 1 Billion valuation and fully diluted(all warrants executed) Oncosec would be valued at around $20/share......but if we assume for a number of other indications we could get a much higher share price.....big demand on the FDA approval could shoot Oncosec into a parabolic market moment. I believe that could happen big time next year.
We need to see the presentation charts from SITC abstract to get more info on the partial responders becoming complete responders. 50% BORR is very good data. The fact that all responders are becoming complete responders over a longer timeframe is a big deal. The market doesn't seem to care right now, but when this leads to a deal next year the mentality will change quickly.
Oncosec remains unloved by the market which will set us up for the biggest move upwards in a lifetime when FDA grants accelerated approval next year. 1000% move up overnight. I am staying put with my holdings for next years good news......FDA approval and licensing deals for Oncosec. When it does move big time it will be unstoppable with investors trying to chase it.
This is where retail panics and loses their shares to the big guys. Funds are in it and will build out larger or new positions and the float will continue to shrink. PISCES will be a winner next year and people will be kicking themselves for not being patient and holding on.
The fact that more partial responders are becoming complete responders over a longer period of time is a very good sign. I can't wait to see the full data and patient charts from SITC. With regards to the multi-gene platform, the publication from AACR this past April showed positive results in a mouse model and stated that would be the foundation for future trials.
If PISCES trial is successfull and Merck goes all in, I would not be surprised to see the multi-gene platform exploited to the fullest in indications such as TNBC, Markell Cell, Head and Neck.
Technical indicators seem very strong with Oncosec now. Does anybody here with technical trading experience have an idea where the share price can move upwards before year end. Oncosec has fallen so far since uplisting to Nasdaq in 2015. if we break through resistance levels, could we rise back to $5 that quickly before PISCES results next year. Just wondering if this is a technical possibility in the nearterm. I am quite certain we would surpass that price easy with positive PISCES results. If we are under extreme accumulation right now and we see a short squeeze, wondering how high this might fly quickly.
Thanks trading.jeff. I was just looking for charts to see where we are at. Nice to see we are above the moving averages.
Barchart reading is a solid BUY again. I believe we made it above the 200 Day moving average which should be very bullish.
https://www.barchart.com/stocks/quotes/ONCS/opinion
The report was from a few months ago...June or July.
Shorts are going to get squeezed next week with SITC data being underestimated.....stock will fly higher.....forget about warrants and shares outstanding....demand for Oncosec shares is only going to grow following SITC presentation and into next year's anticipation of PISCES data. Let the good times roll for Oncosec and shareholders.
HC Wainwright ($6 price target) analysts commented, "We believe preliminary interim data—based on the first 16-20 patients—could be reported in late 2017 or early 2018. Management have indicated that an ORR of at least 30% would be considered a success for the PISCES study. We note that positive results from the interim analysis may allow the company to apply for Breakthrough Therapy designation in patients who have failed anti- PD-1 monotherapies. In addition, OncoSec may report 24-month follow- up data from the Phase 2 investigator-sponsored trial later this year. In the wake of this update, we reiterate our Buy rating and $6 price target. 43% ORR in Phase 2 combo trial. A prior investigator-sponsored Phase 2 combo study of ImmunoPulse IL-12 and Keytruda in 22 metastatic melanoma patients reported positive data. These patients were predicted to have low likelihoods of response to anti-PD-1 monotherapies based on biomarker assays. The results showed a 43% (9/21) ORR at 24 weeks by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. There were 24% (5/21) complete responders and 19% (4/22) partial responders. Of note, nine out of the 22 patients enrolled had prior checkpoint inhibitor therapy; ORR for this subset of patients was 33% (3/9). The data showed that intra-tumoral electroporation of interleukin-12 DNA, combined with pembrolizumab, can effectively alter the tumor microenvironment and increase tumor- specific CD8+ T-cells, which drive a systemic anti-tumor immune response. The combo therapy had an acceptable safety profile and was well tolerated."
I think 30% is well within reach for the PISCES trial and that means commercialization prospects are very highly likely next year. Stock is going to fly. This time for Oncosec has been years in the making....but the time is now....this time for real.
OncoSec data continues to build for Keytruda combination, says Maxim Maxim analyst Jason McCarthy noted that OncoSec (ONCS) presented "positive" data demonstrating that at 6 months the combination of the company's TAVO with Merck's (MRK) Keytruda in melanoma patients that are non-responders to checkpoint therapy induced a best overall response rate of 50%. The Phase 2b registration study with Merck is now underway and good results would be a "significant incentive" for Merck to support the combination, said McCarthy, who keeps a Buy rating and $5 price target on OncoSec shares.
Read more at:
https://thefly.com/landingPageNews.php?id=2625658
If that is correct than I misunderstood that. I'm not trying to post false information. My mistake.
But that does mean Oncosec just collected an additional 5 million from the offering? Is that correct?
If that is true then why on the FORM D filed yesterday does it state:
amount offered: $,4941,500
amount sold: $4,941,500
I took this to mean they were executed.
If I am wrong about this please clarify why the FORM D would state a sold amount.
FORM D states:
"Small Company Offering and Sale of Securities Without Registration"
You are wrong. According to the offering statement:
"Additionally, OncoSec has also agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 3,953,200 shares of common stock at an exercise price of $1.25 per share for a term of 5.5 years. The warrants are immediately exercisable on the date of issuance. The offering is expected to close on or about October 25, 2017, subject to the satisfaction of customary closing conditions".
The form D filed yesterday discloses the exact amount of revenue from the warrants and it matches exactly all the warrants combined from the 3 investors involved in the 7 million offering.
I think you are mistaking other warrants....maybe the Wainwright Warrants.
Nice close green! We are looking great for next week. Monday will be exciting with abstracts released tuesday morning.
This is going to be a real TUG OF WAR today.
THERE SHE GOES. PEOPLE NEED TO LOAD UP BEFORE SITC!
Warrants have been fully executed now by the 3 investor Funds from the recent equity offering. I take this as very BULLISH. The warrants are now out of the way and Oncosec has raised another 5 million so plenty of money in the bank to get us the PISCES interim data next year without another raise. We are now set to run on any positive SITC data. Oncosec doubled their cash reserves with the equity offering on very good terms at the right time.
The consistent increase in Volume....speaks volumes about where we are headed.
Another 50,000 buy just went through. I can't wait to see the SEC updates of ownership in the next few weeks. This is going to get very good.
That is exactly what I was pointing out too Guti. It is obvious that we have turned a corner here. The people who have bought Oncosec in the past are back and in it bigger than ever. That means something, hedge fund or Institution, I'll take it for what it's worth as a good sign.
Looks like a lot of people are willing to let their shares go for 1.20. That is nuts. We are slowly breaking the wall here.
Another 50,000 purchase just went through. Got to be institutions loading up!
I see light at the end of the tunnel now. Very hopeful! Things are about to take a very good turn here. I spent about one entire year not looking at my brokerage account. Like McDonalds...we deserve a break today!
I would only agree with this statement if PISCES trial is a failure next year..... I don't believe it will fail though....and we will have a much much higher valuation.
Oncosec pre split reached around $1 very briefly IN 2013 OR 2014, before crashing down to around the 20 or 30 cent range. Reminds me of how long I have watched this stock.... since pink sheet OTC. I only invested a few hundred dollars in Oncosec for kicks when searching penny stocks.
Yes, right back to 1.19. Sentiment is very positive right now. Looking good.
Right now I think they are betting on a move much higher. Just my opinion. I am hoping.
Just looks like a shakeout today. If shareholders can live through the drop below .90 cents this is nothing. Shareholders stay calm.....will bounce right back.
You are correct DR. Low. These Hedge Funds see a strong move higher coming and that is why they jumped in right now. They might jump right out of course but maybe not and maybe this time the price stays at a higher level. Anson Funds was in Oncosec this time last year and sold out 2 quarters later. Anson is now in Oncosec again but this time with a much larger stake. Maybe they sell two quarters from now or wait for PISCES data next year. I believe Oncosec share price will be higher next year. That is just my opinion though, and I am a long term investor.....smart or dumb that is my own choice. I am not a day trader. I do believe in Oncosec and that they have something pretty great to offer cancer patients that don't respond to Keytruda or Opdivo alone.
Well, they are Funds that see value or they would not be buying.
Oncosec's strategy to change the Merck combo study protocol 2 years ago has brought us to this point.....on track to get an early approval next year, shaving 2 more years off the timeline to an actual commercially approved therapy. This will explode on an approval next year. Tutes know this and jumped in at this low price.
Very Telling that Oncosec terminated the ATM to raise money and 3 funds jump in to take a stake right before SITC. 2 abstracts will be released with possible disruptive data updates. Next week will be fun.
The data next week will be more detailed than just the numbers recently reported. We will get details on more partial responders becoming complete responders in the ongoing Merck combo study. Punit was surprised at the increase in overall response rate. At SITC we will also get more information on durable response rate in the current combo Merck study. The other abstract a day earlier will be data on the multi-gene construct which might surprise the market.....possible disruptive new data.
The Oncosec late breaking abstracts for SITC have attracted Institutional interest since they were announced a few weeks ago.
We are getting ready here for a big move on this data release and subsequently we will be moving higher as we get near to interim data for PISCES next year.
THIS IS BIGTIME!
This should help maintain the share price....now let's see what other Institutions show up that have been buying in lots of 50,000... 20,000... and 10,000 share lots on the open market recently. We will know soon enough. Keep checking whalewisdom.com for updates.
Anson Funds 6.5% stake in Oncosec....had a feeling we might see another one today!
MIGHT SEE ANOTHER STATEMENT OF OWNERSHIP AFTER MARKET TODAY. JUST A FEELING.
Looked like a 25,000 share purchase at 1.19 few minutes ago. 10,000 purchase at 1.19 a few minutes before that one. About to move up.